Rakuten Aspyrian Finds $150M For Cancer Treatments
socalTECH
AUGUST 27, 2018
San Diego-based biotechnology developer Rakuten Aspyrian announced last week that it has raised $150M for its efforts to develop treatments for head and neck cancer. According to the company, the new funds will go towards advancing its lead compound, ASP-1929, into Phase 3 clinical trials. Miguel Garcia-Guzman, Ph.D.
Let's personalize your content